Exclusive Summary

• Backed by EU-EMA GMP and MAs granted across 27 EU nations, enabling immediate "plug-and-play" commercial distribution with zero regulatory delay.
• China's integrated API-to-FDF supply chain provides a significant cost baseline advantage against the originator and other generic peers, ensuring extremely lucrative margins for local partners.
• Perfectly aligned with global ERAS (Enhanced Recovery After Surgery) protocols as a cornerstone opioid-sparing analgesic, directly targeting the massive demand from over 300 million global surgeries annually.
• Extensive EU regulatory dossiers serve as premium endorsements to issue CPPs, facilitating fast-track penetration into highly lucrative emerging markets like LATAM, MENA, and SEA.